<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Diab Vasc Dis Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Diab Vasc Dis Res</journal-id>
    <journal-id journal-id-type="publisher-id">DVR</journal-id>
    <journal-id journal-id-type="hwp">spdvr</journal-id>
    <journal-title-group>
      <journal-title>Diabetes &amp; Vascular Disease Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1479-1641</issn>
    <issn pub-type="epub">1752-8984</issn>
    <publisher>
      <publisher-name>SAGE Publications</publisher-name>
      <publisher-loc>Sage UK: London, England</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7510367</article-id>
    <article-id pub-id-type="pmid">31841030</article-id>
    <article-id pub-id-type="publisher-id">10.1177_1479164119892137</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Prediction of major adverse cardiac, cerebrovascular events in
patients with diabetes after acute coronary syndrome</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5204-0771</contrib-id>
        <name>
          <surname>Baluja</surname>
          <given-names>Aurora</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="aff" rid="aff2-1479164119892137">2</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="author-notes" rid="fn1-1479164119892137">*</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7566-9321</contrib-id>
        <name>
          <surname>Rodríguez-Mañero</surname>
          <given-names>Moisés</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="aff" rid="aff4-1479164119892137">4</xref>
        <xref ref-type="author-notes" rid="fn1-1479164119892137">*</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
        <xref ref-type="corresp" rid="corresp1-1479164119892137"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cordero</surname>
          <given-names>Alberto</given-names>
        </name>
        <xref ref-type="aff" rid="aff4-1479164119892137">4</xref>
        <xref ref-type="aff" rid="aff5-1479164119892137">5</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Kreidieh</surname>
          <given-names>Bahij</given-names>
        </name>
        <xref ref-type="aff" rid="aff6-1479164119892137">6</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Iglesias-Alvarez</surname>
          <given-names>Diego</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>García-Acuña</surname>
          <given-names>Jose M</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="aff" rid="aff4-1479164119892137">4</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Martínez-Gómez</surname>
          <given-names>Alvaro</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Agra-Bermejo</surname>
          <given-names>Rosa</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="aff" rid="aff4-1479164119892137">4</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Alvarez-Rodríguez</surname>
          <given-names>Leyre</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Abou-Jokh</surname>
          <given-names>Charigan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>López-Ratón</surname>
          <given-names>Mónica</given-names>
        </name>
        <xref ref-type="aff" rid="aff7-1479164119892137">7</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gude-Sampedro</surname>
          <given-names>Francisco</given-names>
        </name>
        <xref ref-type="aff" rid="aff8-1479164119892137">8</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Alvarez-Escudero</surname>
          <given-names>Julián</given-names>
        </name>
        <xref ref-type="aff" rid="aff2-1479164119892137">2</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>González-Juanatey</surname>
          <given-names>Jose R</given-names>
        </name>
        <xref ref-type="aff" rid="aff1-1479164119892137">1</xref>
        <xref ref-type="aff" rid="aff3-1479164119892137">3</xref>
        <xref ref-type="aff" rid="aff4-1479164119892137">4</xref>
        <xref ref-type="author-notes" rid="fn2-1479164119892137">†</xref>
      </contrib>
    </contrib-group>
    <aff id="aff1-1479164119892137"><label>1</label>Cardiology Department, Complejo
Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela,
Spain</aff>
    <aff id="aff2-1479164119892137"><label>2</label>Critical Patient Translational Research
Group, Department of Anesthesiology, Intensive Care and Pain Management, Complejo
Hospitalario Universitario, Santiago de Compostela, Spain</aff>
    <aff id="aff3-1479164119892137"><label>3</label>Instituto de Investigación Sanitaria
(IDIS), Universidad de Santiago de Compostela, Santiago de Compostela, Spain</aff>
    <aff id="aff4-1479164119892137"><label>4</label>Centro de Investigación Biomédica en Red
de Enfermedades Cardiovasculares (CIBERCV CB16/11/00226-CB16/11/00420), Madrid,
Spain</aff>
    <aff id="aff5-1479164119892137"><label>5</label>Cardiology Department, Hospital
Universitario de San Juan. Alicante, Spain</aff>
    <aff id="aff6-1479164119892137"><label>6</label>University of Miami/JFK Medical Center
Palm Beach Regional GME Consortium, Atlantis, FL, USA</aff>
    <aff id="aff7-1479164119892137"><label>7</label>Board of Education, Galician Government,
Xunta de Galicia, Spain</aff>
    <aff id="aff8-1479164119892137"><label>8</label>Clinical Epidemiology Unit, University
Clinical Hospital of Santiago, Santiago de Compostela, Spain</aff>
    <author-notes>
      <corresp id="corresp1-1479164119892137">Moisés Rodríguez-Mañero, Cardiology
Department, Complejo Hospitalario Universitario de Santiago de Compostela,
Travesía da Choupana s/n, Santiago de Compostela 15706, Spain. Email:
<email>moirmanero@gmail.com</email>.</corresp>
      <fn fn-type="equal" id="fn1-1479164119892137">
        <label>*</label>
        <p>Both authors contributed equally to the elaboration of the manuscript.</p>
      </fn>
      <fn fn-type="equal" id="fn2-1479164119892137">
        <label>†</label>
        <p>These authors take responsibility for all aspects of the reliability and
freedom from bias of the data presented and their discussed
interpretation.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>16</day>
      <month>12</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="collection">
      <season>Jan-Feb</season>
      <year>2020</year>
    </pub-date>
    <volume>17</volume>
    <issue>1</issue>
    <elocation-id>1479164119892137</elocation-id>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
      <license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <sec id="section1-1479164119892137">
        <title>Background and objectives:</title>
        <p>The risk of major adverse cardiac and cerebrovascular events following acute
coronary syndrome is increased in people with diabetes. Predicting
out-of-hospital outcomes upon follow-up remains difficult, and no simple,
well-validated tools exist for this population at present. We aim to
evaluate several factors in a competing risks model for actionable
evaluation of the incidence of major adverse cardiac and cerebrovascular
events in diabetic outpatients following acute coronary syndrome.</p>
      </sec>
      <sec id="section2-1479164119892137">
        <title>Methods:</title>
        <p>Retrospective analysis of consecutive patients admitted for acute coronary
syndrome in two centres. A Fine–Gray competing risks model was adjusted to
predict major adverse cardiac and cerebrovascular events and all-cause
mortality. A point-based score is presented that is based on this model.</p>
      </sec>
      <sec id="section3-1479164119892137">
        <title>Results:</title>
        <p>Out of the 1400 patients, there were 783 (55.9%) with at least one major
adverse cardiac and cerebrovascular event (417 deaths). Of them, 143 deaths
were due to non-major adverse cardiac and cerebrovascular events. Predictive
Fine–Gray models show that the ‘PG-HACKER’ risk factors (gender, age,
peripheral arterial disease, left ventricle function, previous congestive
heart failure, Killip class and optimal medical therapy) were associated to
major adverse cardiac and cerebrovascular events.</p>
      </sec>
      <sec id="section4-1479164119892137">
        <title>Conclusion:</title>
        <p>The PG-HACKER score is a simple and effective tool that is freely available
and easily accessible to physicians and patients. The PG-HACKER score can
predict major adverse cardiac and cerebrovascular events following acute
coronary syndrome in patients with diabetes.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>Diabetes mellitus</kwd>
      <kwd>myocardial infarction</kwd>
      <kwd>left ventricle ejection fraction</kwd>
      <kwd>cardiovascular death</kwd>
      <kwd>major adverse cardiac and cerebrovascular events</kwd>
      <kwd>score</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>January-February 2020</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>typesetter</meta-name>
        <meta-value>ts1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="section5-1479164119892137">
    <title>Introduction</title>
    <p>Diabetes mellitus (DM) is a pro-inflammatory state that promotes and accelerates atherosclerosis.<sup><xref rid="bibr1-1479164119892137" ref-type="bibr">1</xref></sup> It is well known that people with diabetes and a history of acute coronary
syndrome (ACS) are at higher risk of death from cardiovascular causes than from
non-cardiovascular causes.<sup><xref rid="bibr2-1479164119892137" ref-type="bibr">2</xref>,<xref rid="bibr3-1479164119892137" ref-type="bibr">3</xref></sup>
In people with diabetes, the risk of death following ACS is increased compared to
non-diabetics despite similar infarct size and left ventricular ejection fraction (LVEF).<sup><xref rid="bibr4-1479164119892137" ref-type="bibr">4</xref></sup> In VALsartan In Acute myocardial iNfarcTion (VALIANT) sub-study, for any
given LVEF, the presence of DM was associated with a 37% higher risk of all-cause
mortality with an adjusted hazard ratio (HR) of 1.37 (95% confidence interval (CI): 1.25–1.51).<sup><xref rid="bibr5-1479164119892137" ref-type="bibr">5</xref></sup> Post-infarction, patients from Germany and Finland with heart failure (HF)
and reduced LVEF (HFrEF) demonstrated a significantly higher incidence of cardiac
death in the presence of comorbid DM (HR: 3.8, 95% CI: 2.4–5.8;
<italic>p</italic> &lt; 0.001). Moreover, the incidence of sudden cardiac death
(SCD) in patients with diabetes with LVEF &gt; 35% was similar to its incidence in
non-diabetics with LVEF ⩽ 35% (4.1% vs 4.9%, respectively).<sup><xref rid="bibr6-1479164119892137" ref-type="bibr">6</xref></sup></p>
    <p>Upon inpatient admission with ACS, risk stratification is often employed to predict
in-hospital mortality risk. The Global Registry of Acute Coronary Events (GRACE)
score is commonly used for this purpose and has been shown to offer good predictive
power for in-hospital mortality in diabetic patients as well.<sup><xref rid="bibr7-1479164119892137" ref-type="bibr">7</xref></sup> Unfortunately, forecasting out-of-hospital major adverse cardiac and
cerebrovascular events (MACCE) upon follow-up remains difficult and no simple,
well-validated tool exists for this population at present. The objective of this
study was to examine the risk factors that increase the incidence of MACCE in the
diabetic population following ACS and facilitate risk stratification of these
patients using a simplified, easily accessible risk score.</p>
  </sec>
  <sec sec-type="methods" id="section6-1479164119892137">
    <title>Methods</title>
    <sec id="section7-1479164119892137">
      <title>Study design</title>
      <p>This was a retrospective analysis of all consecutive patients admitted for ACS in
two different centres. A total of 1562 patients with diabetes who were admitted
for ACS between November 2003 and January 2017 were included. Both centres are
tertiary hospitals with coronary units and 24 h availability of coronary
interventionism. The study was approved by our Ethical Research Committee and
conformed to the ethical guidelines of the 1975 Declaration of Helsinki.</p>
    </sec>
    <sec id="section8-1479164119892137">
      <title>Definitions of variables of interest</title>
      <p>ACS was defined as the presence of typical clinical symptoms, specifically chest
pain and electrocardiographic (ECG) changes indicative of myocardial
ischaemia/lesion and elevation of serum markers of myocardial damage.<sup><xref rid="bibr8-1479164119892137" ref-type="bibr">8</xref></sup> ACS was stratified into ST-elevation myocardial infarction (STEMI)- and
non-STEMI-based on ECG findings. For the antecedent of previous coronary heart
disease, patients needed to have a clinical diagnosis of myocardial infarction
(MI), stable or unstable angina or angina-driven coronary revascularization.
History of HF was coded if patients had at least one hospitalization with this
main diagnosis at discharge in the past. It was also identified in those with
typical signs and symptoms of HF who had compatible imaging findings (X-ray or
echocardiogram). According to current guidelines<sup><xref rid="bibr9-1479164119892137" ref-type="bibr">9</xref></sup> and previous reports,<sup><xref rid="bibr10-1479164119892137" ref-type="bibr">10</xref></sup> optimal medical therapy (OMT) at discharge included joint implementation
of these four treatments: antiplatelets, statins, beta-blockers and
angiotensin-converter enzyme inhibitors or mineralocorticoid receptor
antagonists (MRAs). LVEF was divided into four categories: LVEF &gt; 51%,
LVEF = 41%–51%, LVEF = 30%–40% and LVEF &lt; 30%. A MACCE was defined as
cardiovascular mortality, new MI, SCD, cerebrovascular accident (CVA) or HF
episode.</p>
    </sec>
    <sec id="section9-1479164119892137">
      <title>Data collection</title>
      <p>Data on risk factors, medical history, complementary testing, diagnostics and
treatment at discharge were collected from all patients by trained medical
staff. The diagnostic and therapeutic ACS protocols in both centres included
blood tests in the emergency department and the first fasting state following
hospital admission. Glomerular filtration rate was estimated from serum
creatinine values with the Modification of Diet in Renal Disease Study equation.<sup><xref rid="bibr11-1479164119892137" ref-type="bibr">11</xref></sup> LVEF was documented by imaging at least 3 calendar months after the most
recent MI, percutaneous coronary intervention (PCI) or coronary artery bypass
graft (CABG) surgery.</p>
    </sec>
    <sec id="section10-1479164119892137">
      <title>Follow-up and outcome measures</title>
      <p>Post-discharge follow-up conformed to a well-established protocol in each centre.
The main endpoints assessed through follow-up were the major cardiovascular
events defined above. Follow-up was completed via phone calls, review of
electronic medical records and institutional databases. Alive status was
confirmed by phone calls in the absence of appropriate medical reports within
the institution.</p>
    </sec>
    <sec id="section11-1479164119892137">
      <title>Statistical analysis</title>
      <p>Quantitative variables are presented as mean and standard deviation (SD).
Categorical variables are presented as frequencies and percentages. Pearson’s
chi-square test was used to compare observed frequencies between categorical
variables, whereas Kruskal–Wallis test was chosen to compare continuous data
grouped by variable with &gt;2 levels. Multiple testing was addressed using a
false discovery ratio (FDR) control with the Benjamini–Hochberg procedure. All
analyses were performed using R v.3.4 (R Core Team, Vienna, Austria) with the
‘cmprsk’ and ‘riskRegression’ packages.</p>
      <sec id="section12-1479164119892137">
        <title>Competing risks models</title>
        <p>A competing risk (CR) is an event whose occurrence either precludes the
occurrence of another event under examination or fundamentally alters the
probability of occurrence of this other event.<sup><xref rid="bibr12-1479164119892137" ref-type="bibr">12</xref></sup> The cause-specific hazard at time <italic>t</italic> (Cox CRs model)
is defined by the instantaneous risk of failure per time unit due to one
risk, as if there were no competing events. However, the HRs obtained are
not directly related to the prediction of the cumulative incidence; thus,
they are not suitable to predict a given patient’s global risk.</p>
        <p>On the other hand, the HR of the subdistribution (Fine &amp; Gray CR model)<sup><xref rid="bibr13-1479164119892137" ref-type="bibr">13</xref></sup> is interpreted as the probability of observing an event of interest
in the next time interval, while knowing that either the event of interest
did not happen until then or that a competing event was observed.
Unfortunately, the absolute values of the regression coefficients in the
Fine–Gray model have no direct interpretation. Sub-distribution HR denotes
the direction but does not directly provide the magnitude of the effect of
the covariate on the cumulative incidence function (CIF). Cause-specific
hazard models (Cox-CR) are better suited for studying the aetiology of
diseases (the risk independently posed by every covariate), whereas the Fine
&amp; Gray model has a use in predicting an individual’s risk (incidence) of
an event. Both models were implemented and compared with the GRACE
score.</p>
      </sec>
      <sec id="section13-1479164119892137">
        <title>Risk score</title>
        <p>Fine–Gray models are suitable to develop risk scores that consider CRs.
Accordingly, we developed a simplified, points-based risk-scoring system
standardized by age, following Framingham’s score framework and state-of-the
art methodology by Austin et al.<sup><xref rid="bibr14-1479164119892137" ref-type="bibr">14</xref></sup> This allows us to determine the incidence of the outcome within a
specified duration of time that is associated with each of the possible
values of the risk-scoring system. Finally, we studied and compared the
concordance (c-index) and calibration properties of the final models and the
score at different follow-up times.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="results" id="section14-1479164119892137">
    <title>Results</title>
    <sec id="section15-1479164119892137">
      <title>Study population and competing events</title>
      <p>The mean age of our patients was 69.6 ± 10.8, and 415 (29.6%) were female. The
mean LVEF was 53.9 ± 11.7 (<xref rid="table1-1479164119892137" ref-type="table">Table 1</xref>). The mean follow-up was 1636.3 ± 1001.4 days.</p>
      <table-wrap id="table1-1479164119892137" orientation="portrait" position="float">
        <label>Table 1.</label>
        <caption>
          <p>Population characteristics.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="10.1177_1479164119892137-table1"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" rowspan="1" colspan="1">Variable</th>
                <th align="left" rowspan="1" colspan="1">Category</th>
                <th align="left" rowspan="1" colspan="1">Result</th>
                <th align="left" rowspan="1" colspan="1">Variable</th>
                <th align="left" rowspan="1" colspan="1">Category</th>
                <th align="left" rowspan="1" colspan="1">Result</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Gender – female</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">415 (29.6%)</td>
                <td rowspan="1" colspan="1">Number of vessels</td>
                <td rowspan="1" colspan="1">0 or 1 vessel</td>
                <td rowspan="1" colspan="1">750 (53.6%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age (mean ± SD)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">69.6 ± 10.8</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">2 or 3 vessels</td>
                <td rowspan="1" colspan="1">574 (41%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BMI (mean ± SD)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">29.9 ± 11.9</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Left main + 0/1 vessel</td>
                <td rowspan="1" colspan="1">14 (1%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hypertension</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">1020 (72.9%)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Left main + 2/3 vessels</td>
                <td rowspan="1" colspan="1">62 (4.4%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Smoker</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">258 (18.4%)</td>
                <td rowspan="1" colspan="1">Complete revascularization</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">520 (37.1%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">LVEF (mean ± SD)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">53.9 ± 11.7</td>
                <td rowspan="1" colspan="1">CABG</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">76 (5.4%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">LVEF category</td>
                <td rowspan="1" colspan="1">1. LVEF &gt; 51%</td>
                <td rowspan="1" colspan="1">934 (66.7%)</td>
                <td rowspan="1" colspan="1">Optimal medical therapy</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">593 (42.4%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">2. LVEF = 41%–51%</td>
                <td rowspan="1" colspan="1">213 (15.2%)</td>
                <td rowspan="1" colspan="1">MACCE in follow-up</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">783 (55.9%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">3. LVEF = 30%–40%</td>
                <td rowspan="1" colspan="1">204 (14.6%)</td>
                <td rowspan="1" colspan="1">MI in follow-up</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">293 (20.9%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">4. LVEF ⩽ 30%</td>
                <td rowspan="1" colspan="1">49 (3.5%)</td>
                <td rowspan="1" colspan="1">CVA in follow-up</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">75 (5.4%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Peripheral arterial disease</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">209 (14.9%)</td>
                <td rowspan="1" colspan="1">CHF in follow-up</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">374 (26.7%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Previous CHF</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">95 (6.8%)</td>
                <td rowspan="1" colspan="1">Sudden death</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">40 (2.9%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">CKD</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">147 (10.5%)</td>
                <td rowspan="1" colspan="1">Days of follow-up (mean ± SD)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">1636.3 ± 1001.4</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">GRACE (mean ± SD)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">148.7 ± 36.5</td>
                <td rowspan="1" colspan="1">Deaths</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">508 (36.3%)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Killip</td>
                <td rowspan="1" colspan="1">1</td>
                <td rowspan="1" colspan="1">1072 (76.6%)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">2</td>
                <td rowspan="1" colspan="1">230 (16.4%)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">3</td>
                <td rowspan="1" colspan="1">77 (5.5%)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">4</td>
                <td rowspan="1" colspan="1">21 (1.5%)</td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="table-fn1-1479164119892137">
            <p>BMI: body mass index; CABG: coronary artery bypass grafting; CHF:
congestive heart failure; CKD: chronic kidney disease; CVA:
cerebrovascular accident; LVEF: left ventricle ejection fraction;
MACCE: major adverse cardiac and cerebrovascular events; MI:
myocardial infarction; SD: standard deviation; GRACE: Global
Registry of Acute Coronary Events.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Out of the 1400 patients, there were 783 (55.9%) with at least one MACCE event
(417 of them resulting in death). Of them, there were 374 (26.7%) HF episodes
during follow-up (8 of them resulting in death), and 75 (5.4%) CVA episodes
(none of them resulting in death). A total of 143 deaths were due to non-MACCE
causes (<xref rid="table1-1479164119892137" ref-type="table">Table 1</xref>,
<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Online Appendix 5</ext-link>).</p>
      <p>As shown in <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Online Appendix 1</ext-link>, the proportion of MACCE events increased with
lower LVEF (<italic>p</italic> &lt; 0.0001). There were no significant
differences regarding treatment, except for diuretic therapy. Also, lower LVEF
strata were associated with older patients (<italic>p</italic> = 0.0006) and
with lower body mass index (BMI).</p>
    </sec>
    <sec id="section16-1479164119892137">
      <title>Risk models of MACCE versus all-cause mortality</title>
      <p>For time-to-event models, we considered the risk of MACCE versus all-cause
mortality as competing events. Multivariable analyses were adjusted by gender,
age, diagnosis of hypertension, categorized LVEF, diagnosis of peripheral artery
disease, history of congestive HF, chronic kidney disease (CKD), OMT and Killip
class during ACS.</p>
      <p>As shown in <xref rid="table2-1479164119892137" ref-type="table">Table 2</xref>,
Killip class, lower LVEF, CKD and age were all associated with an increased
mortality rate. Predictive Fine–Gray models (CIF) showed that age, lower LVEF,
peripheral artery disease and Killip class were associated with higher MACCE
incidence (presenting higher sub-distributional hazards) (<xref ref-type="fig" rid="fig1-1479164119892137">Figure 1(a)</xref>). Female gender and OMT were
associated with lower mortality rates as well as longer event-free times. The
incidence of cardiovascular outcomes in post-MI patients with diabetes with LVEF
35%–50% is comparable at &gt;3 years to that seen in LVEF &lt; 35%. Moreover,
LVEF &gt; 40% had a MACCE incidence that was 17% lower at 5 years [<xref ref-type="fig" rid="fig2-1479164119892137">Figure 2(b)</xref>]. Conversely,
lower LVEF does not increase non-cardiovascular mortality [<xref ref-type="fig" rid="fig2-1479164119892137">Figure 2(a)</xref>]. The number of affected
vessels and the presence of incomplete revascularization or coronary bypass
procedure were not independently associated with MACCE incidence.</p>
      <table-wrap id="table2-1479164119892137" orientation="portrait" position="float">
        <label>Table 2.</label>
        <caption>
          <p>Competing risks models.</p>
        </caption>
        <alternatives>
          <graphic xlink:href="10.1177_1479164119892137-table2"/>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
              <col align="char" char="." span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">CSH event-free survival</th>
                <th align="left" rowspan="1" colspan="1">CSH mortality</th>
                <th align="left" rowspan="1" colspan="1">CSH MACCE</th>
                <th align="left" rowspan="1" colspan="1">CIF mortality</th>
                <th align="left" rowspan="1" colspan="1">CIF MACCE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Gender – female</td>
                <td rowspan="1" colspan="1">0.88 [0.75, 1.02]</td>
                <td rowspan="1" colspan="1">0.91 [0.80, 1.03]</td>
                <td rowspan="1" colspan="1">0.95 [0.80, 1.15]</td>
                <td rowspan="1" colspan="1">1.11 [0.69, 1.77]</td>
                <td rowspan="1" colspan="1">0.87 [0.74, 1.03]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Age</td>
                <td rowspan="1" colspan="1">1.04 [1.03, 1.05]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">***</xref></td>
                <td rowspan="1" colspan="1">1.02 [1.01, 1.02]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">***</xref></td>
                <td rowspan="1" colspan="1">1.00 [0.99, 1.01]</td>
                <td rowspan="1" colspan="1">1.03 [1.00, 1.05]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.03 [1.02, 1.04]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">***</xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Hypertension</td>
                <td rowspan="1" colspan="1">1.04 [0.88, 1.22]</td>
                <td rowspan="1" colspan="1">1.00 [0.88, 1.13]</td>
                <td rowspan="1" colspan="1">0.90 [0.75, 1.08]</td>
                <td rowspan="1" colspan="1">0.78 [0.47, 1.30]</td>
                <td rowspan="1" colspan="1">1.12 [0.95, 1.33]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Smoker</td>
                <td rowspan="1" colspan="1">1.12 [0.91, 1.37]</td>
                <td rowspan="1" colspan="1">1.01 [0.86, 1.18]</td>
                <td rowspan="1" colspan="1">1.00 [0.81, 1.23]</td>
                <td rowspan="1" colspan="1">1.53 [0.82, 2.85]</td>
                <td rowspan="1" colspan="1">0.99 [0.79, 1.23]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">LVEF category number</td>
                <td rowspan="1" colspan="1">1.11 [1.02, 1.21]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.07 [0.99, 1.15]</td>
                <td rowspan="1" colspan="1">0.98 [0.87, 1.10]</td>
                <td rowspan="1" colspan="1">0.92 [0.72, 1.19]</td>
                <td rowspan="1" colspan="1">1.12 [1.02, 1.23]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Peripheral arterial disease</td>
                <td rowspan="1" colspan="1">1.30 [1.09, 1.56]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.16 [0.99, 1.37]</td>
                <td rowspan="1" colspan="1">1.04 [0.79, 1.37]</td>
                <td rowspan="1" colspan="1">1.30 [0.77, 2.21]</td>
                <td rowspan="1" colspan="1">1.25 [1.02, 1.52]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Previous CHF</td>
                <td rowspan="1" colspan="1">1.47 [1.15, 1.88]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.41 [1.10, 1.80]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.30 [0.80, 2.09]</td>
                <td rowspan="1" colspan="1">1.74 [0.91, 3.33]</td>
                <td rowspan="1" colspan="1">1.26 [0.93, 1.70]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">CKD</td>
                <td rowspan="1" colspan="1">1.49 [1.21, 1.83]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">**</xref></td>
                <td rowspan="1" colspan="1">1.27 [1.04, 1.55]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.29 [0.93, 1.81]</td>
                <td rowspan="1" colspan="1">1.88 [1.09, 3.24]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">1.21 [0.94, 1.55]</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Killip</td>
                <td rowspan="1" colspan="1">1.30 [1.17, 1.44]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">***</xref></td>
                <td rowspan="1" colspan="1">1.19 [1.08, 1.31]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">**</xref></td>
                <td rowspan="1" colspan="1">1.13 [0.96, 1.33]</td>
                <td rowspan="1" colspan="1">1.27 [0.94, 1.72]</td>
                <td rowspan="1" colspan="1">1.19 [1.06, 1.35]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Optimal medical therapy</td>
                <td rowspan="1" colspan="1">0.81 [0.70, 0.94]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
                <td rowspan="1" colspan="1">0.98 [0.88, 1.10]</td>
                <td rowspan="1" colspan="1">1.16 [0.99, 1.36]</td>
                <td rowspan="1" colspan="1">0.70 [0.43, 1.14]</td>
                <td rowspan="1" colspan="1">0.85 [0.73, 1.00]<xref ref-type="table-fn" rid="table-fn3-1479164119892137">*</xref></td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="table-fn2-1479164119892137">
            <p>CABG: coronary artery bypass grafting; CHF: congestive heart failure;
CIF: cumulative incidence function (Fine–Gray competing risks
models); CKD: chronic kidney disease; CSH: cause-specific hazard
(Cox competing risks models); LVEF: left ventricle ejection
fraction; MACCE: major adverse cardiac and cerebrovascular
events.</p>
          </fn>
          <fn id="table-fn3-1479164119892137">
            <label>*</label>
            <p>Values in the range 0.001 to &lt;0.05; **values in the range
0.0001–0.001; ***values &lt;0.0001.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <fig id="fig1-1479164119892137" orientation="portrait" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>(a) Cumulative incidence of MACCE. (b) Calibration plot for risk at
10 years of the two models and the scores.</p>
        </caption>
        <graphic xlink:href="10.1177_1479164119892137-fig1"/>
      </fig>
      <fig id="fig2-1479164119892137" orientation="portrait" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Cumulative incidence of MACCE and non-cardiac death across different LVEF
categories.</p>
        </caption>
        <graphic xlink:href="10.1177_1479164119892137-fig2"/>
      </fig>
    </sec>
    <sec id="section17-1479164119892137">
      <title>Score</title>
      <p>A points-based risk-scoring system – PG-HACKER score – was developed with the
following variables (<ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Online Appendix 2</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Online Appendix 3</ext-link>): gender (–1 point for female), age
[points = (age – 20)/5], previous congestive HF (1 point), peripheral artery
disease (1 point) and Killip class during ACS episode (K1 = 0, K2 = 1, K3 = 2
and K4 = 3 points). EF category (&gt;51% = 0, 41%–51% = 1 and &lt;41%= 2) and
OMT (–1 point). <xref ref-type="fig" rid="fig1-1479164119892137">Figure
1(a)</xref> and <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Online Appendix 3</ext-link> show the mortality estimates associated with
each score by year of follow-up. To facilitate its use in the clinical setting,
we wrote a simplified HTML calculator and Android app based on the MACCE risk
score for people with diabetes (PG-HACKER), that can be freely online at
medicalc.github.io/pghacker (printed in PDF as <ext-link ext-link-type="uri" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/1479164119892137">Supplemental Online material</ext-link> for review).</p>
    </sec>
    <sec id="section18-1479164119892137">
      <title>Model evaluation: concordance and calibration</title>
      <p>In the analysis of time-to-event data, a pair of patients is called concordant if
the risk of the event predicted by a model is lower for the patient who
experiences the event later in time. The concordance probability (C-index) is
the frequency of concordant pairs among all pairs of subjects. It can be used to
measure and compare the (overall) pre-test discriminative power of risk
prediction models.</p>
      <p>Estimates of the concordance index were 0.68 for the CR model, 0.67 for the
score, 0.63 for the GRACE score and 0.77 for the Cox model. The calibration of
the model was assessed comparing the predicted probability of MACCE to the
observed probability of MACCE within 5 years, across the 10 deciles of predicted
risk. The Fine-Gray risk model (FGR) model and the score displayed a good
calibration at 10 years [<xref ref-type="fig" rid="fig1-1479164119892137">Figure
1(b)</xref>], albeit with risk overprediction at higher deciles of predicted
risk (very high-risk patients). GRACE score exhibited the worst calibration of
all models, especially at higher risk patients.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="section19-1479164119892137">
    <title>Discussion</title>
    <p>In this study, we examined, in a real-world cohort, the incidence of MACCE in the
diabetic population following ACS. Our data confirm that patients with diabetes with
previous ACS are much more likely to have MACCE events than to die of other causes.
Moreover, for the first time, we provide a simple and effective score (named
PG-HACKER) to predict MACCE following ACS in patients with diabetes. This may help
practitioners to monitor changes in modifiable factors to assess the impact of
medical interventions. Classical markers used in patients without DM such as the
LVEF lose predictive capacities when taken alone. Such markers must be combined with
multiple clinical parameters in order to accurately predict outcomes in this
population. The recently published EUROASPIRE V study<sup><xref rid="bibr15-1479164119892137" ref-type="bibr">15</xref></sup> highlights the wide margin that still exists for improvement in secondary
prevention after ACS. This proposed score aims to step forward towards more
personalized medicine. Further investigations will now be needed to address whether
mitigation of these conditions associated with worse outcomes may prove beneficial
in reducing MACCE incidence.</p>
    <sec id="section20-1479164119892137">
      <title>The utility of risk scores for secondary prevention</title>
      <p>Beyond mere risk prediction and stratification, individualized risk scores can be
used in clinical practice to monitor changes in modifiable factors and to assess
the impact of medical interventions. Currently, the GRACE logistic score is the
most widespread in ACS. Although it predicts mortality, it has shown only
slightly lower performance compared to the models presented for MACCE prediction
in our cohort. However, it carries several disadvantages for outpatient
follow-up. First, it relies entirely on factors that must be present at
admission and cannot be recalculated unless a new admission due to ACS takes
place. Hence, the GRACE score may be of less clinical utility for outpatient
visits, where changes in risk factors may dynamically modify MACCE incidence.
Moreover, previous studies have focused on cardiovascular mortality without
considering death due to other causes as a CR, which may induce bias in
predictions. Taking this into account, we evaluated several factors in a CRs
model aimed to actionable, dynamic outpatient evaluation. Specifically, OMT as a
covariable may enable treatment effect assessment for novel drugs. Our study
also shows that intermediate LVEF has similar MACCE outcomes to LVEF ⩽ 30%,
opening the door for more aggressive interventions for sudden death prevention
in those patients.</p>
    </sec>
    <sec id="section21-1479164119892137">
      <title>MACCE prediction in the diabetic population post-ACS</title>
      <p>HF patients with a history of ACS exhibit poorer outcomes with progressive
reduction in LVEF.<sup><xref rid="bibr16-1479164119892137" ref-type="bibr">16</xref>,<xref rid="bibr17-1479164119892137" ref-type="bibr">17</xref></sup> Savonitto et al. determined that in patients with diabetes
with ACS, mortality prediction was dominated by markers of cardiac dysfunction.
The most powerful predictor identified was N-terminal prohormone of brain
natriuretic peptide (NT-ProBNP).<sup><xref rid="bibr18-1479164119892137" ref-type="bibr">18</xref></sup> Similarly, Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA)
trial data support the conclusion that brain natriuretic peptide (BNP) and
NT-ProBNP are powerful predictors of HF, MI, stroke and death.<sup><xref rid="bibr19-1479164119892137" ref-type="bibr">19</xref></sup> Other risk factors they identified included age, prior HF and
albuminuria. The Multinational MONItoring of trends and determinants in
CArdiovascular disease (MONICA) study showed that mortality from acute MI in
people with diabetes is four times higher in men and seven times higher in women
than their non-diabetic counterparts.<sup><xref rid="bibr20-1479164119892137" ref-type="bibr">20</xref></sup></p>
      <p>In our study, worsening outcomes with a progressive reduction in LVEF held in the
diabetic population as well. As expressed in the PG-HACKER risk score, left
ventricular function is an important predictor of outcomes, but DM is strongly
associated with HF and death irrespective of LVEF. As such, the ventricular
function must be combined with multiple clinical parameters (gender, age,
hypertension, peripheral arterial disease (PAD), previous congestive HF, CKD and
Killip class) in order to accurately predict outcomes in this population.</p>
    </sec>
    <sec id="section22-1479164119892137">
      <title>Risk factor modification</title>
      <p>We believe that one of the most substantial benefits of the PG-HACKER score is to
provide an easily accessible awareness tool for both the provider and the
patient alike. It was previously demonstrated that a designated outpatient
clinic for high-risk ACS improves long-term prognosis and largely reduces MACCE
incidence and hospital readmissions.<sup><xref rid="bibr21-1479164119892137" ref-type="bibr">21</xref></sup> Quantification of risk through the PG-HACKER score may provide a more
concrete understanding of the situation as well as the incentive to deliver
aggressive prescription and adherence to OMT.</p>
      <p>Glucose and insulin resistance are not the only targets available in our attempts
to reduce MACCE following ACS in people with diabetes. The PG-HACKER score
highlights multiple conditions that appear to contribute independently to MACCE
risk in this cohort. Stringent management of all these conditions through
special monitoring and implementation of aggressive treatment algorithms may
prove beneficial.</p>
      <p>As described above, one of the most prominent contributors to MACCE in patients
with diabetes post-ACS is the presence and degree of HF. Sacubitril–valsartan is
a drug that reduces the risk of cardiovascular death by 20% in patients with HF
and LVEF &lt; 40%.<sup><xref rid="bibr22-1479164119892137" ref-type="bibr">22</xref></sup> Furthermore, this treatment has been related to lower ventricular
arrhythmias in patients with implantable cardioverter defibrillator
(ICD).<sup><xref rid="bibr23-1479164119892137" ref-type="bibr">23</xref>,<xref rid="bibr24-1479164119892137" ref-type="bibr">24</xref></sup> The clinical effect of sacubitril–valsartan in post-ACS is
currently being investigated in the Prospective ARNI versus ACE Inhibitor Trial
to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) trial,<sup><xref rid="bibr25-1479164119892137" ref-type="bibr">25</xref></sup> and outcomes pertaining to the diabetic population may prove particularly
interesting. Similarly, an endless number of risk factor modification regimens
in optimizing blood pressure control, HF, PAD and CKD may hold research promise
in the future.</p>
    </sec>
    <sec id="section23-1479164119892137">
      <title>SCD</title>
      <p>Ubiquitously, current data seem to indicate that patients with diabetes are at a
significant risk for SCD even if they have moderately reduced/mid-range LVEF.<sup><xref rid="bibr21-1479164119892137" ref-type="bibr">21</xref></sup> As such, this population may be one that benefits from broader
indications for ICD implantation than those dictated by current guidelines. The
results of the PRE-DETERMINE Study provided contemporary estimates of sudden
arrhythmic death (SAD) in patients with coronary heart disease without severe
systolic dysfunction. In their cohort of patients with coronary heart disease
and LVEF greater than 30%–35%, SAD accounted for approximately one-fifth of
total mortality and was the most common mode of cardiovascular death.<sup><xref rid="bibr2-1479164119892137" ref-type="bibr">2</xref></sup> Mid-range left ventricular function (LVEF 40%–49%) was more strongly
associated with SAD than non-SAD, whereas age and New York Heart Association
(NYHA) class II HF were more strongly associated with non-SAD. In the diabetic
population, the already launched Multicenter Automatic Defibrillator
Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator
(MADIT S-ICD) study is designed to test the hypothesis that post-MI, patients
with diabetes ⩾65 years of age, with an ejection fraction of 36%–49% will attain
survival benefit from the implantation of a subcutaneous ICD.<sup><xref rid="bibr26-1479164119892137" ref-type="bibr">26</xref></sup> Shortly, we may see shifting ICD recommendations for people with diabetes
with mid-range EF if pending data continue to support such trends. However, we
believe that the true impact of ICD therapy must be interpreted in the context
of the medical regimen implemented. The score herein proposed could serve to
identify those at higher risk and who may stand to benefit from the most
aggressive medical therapy following ACS.</p>
    </sec>
    <sec id="section24-1479164119892137">
      <title>Limitations</title>
      <p>The present study has several limitations that deserve mention. Echocardiography
was done in the setting of routine clinical practice and, for this reason, was
limited to a focused assessment of cardiac structure and function. Moreover,
evaluation of LVEF could not be standardized and therefore may have been subject
to variations among different operators that may have resulted in the
misclassification of some patients. Importantly, standardized reassessment of
LVEF was not prespecified in the study design, and we cannot comment
specifically on the impact of changes in LVEF and interval risk of death.
Although all patients underwent a transthoracic echocardiogram, for a minority
of them (mostly in order to assess LVEF in dubious cases or to rule out MI
complications), a cardiac magnetic resonance (CMR) was also performed (n = 122
patients, 8.7%). From our point of view, due to the small amount of patients
with both examinations and the correlation of both techniques, this fact should
not have affected, particularly, the conclusion of the study. The diagnosis of
HF was not centrally validated, and a central committee did not determine the
cause of death. Patients with non-ischemic cardiomyopathy are at risk for
cardiovascular mortality, and our findings may not be generalizable to this
population. Furthermore, the process of creating a score implies dichotomizing
continuous data with subsequent information loss. Risk overprediction of
very-high-risk patients could also lead to overinflate the effect of novel
interventions aimed at those patients. This is a known issue in routinely used scores<sup><xref rid="bibr27-1479164119892137" ref-type="bibr">27</xref></sup> to which single-number calibration measurements, such as the
Hosmer–Lemeshow test, do not offer further information. In this regard, specific
cohorts of very high-risk patients could offer novel risk calibration features
in this subpopulation.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="section25-1479164119892137">
    <title>Conclusion</title>
    <p>The PG-HACKER score is a simple and effective tool that is freely available and
easily accessible to predict MACCE following ACS in patients with diabetes. Above
all, we believe that the utility of this score will come from spreading awareness to
the patient and physician alike. In identifying the conditions associated with worse
outcomes, future investigation to mitigate these conditions may prove beneficial in
reducing MACCE incidence.</p>
  </sec>
  <sec sec-type="supplementary-material" id="section26-1479164119892137" specific-use="figshare">
    <title>Supplemental Material</title>
    <supplementary-material content-type="local-data" id="suppl1-1479164119892137">
      <caption>
        <title>Online_appendix_1_Table – Supplemental material for Prediction of major
adverse cardiac, cerebrovascular events in patients with diabetes after
acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_1_Table.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_1_Table for Prediction of major adverse
cardiac, cerebrovascular events in patients with diabetes after acute coronary
syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto Cordero, Bahij
Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro Martínez-Gómez,
Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh, Mónica
López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl2-1479164119892137">
      <caption>
        <title>Online_appendix_2_Table – Supplemental material for Prediction of major
adverse cardiac, cerebrovascular events in patients with diabetes after
acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_2_Table.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_2_Table for Prediction of major adverse
cardiac, cerebrovascular events in patients with diabetes after acute coronary
syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto Cordero, Bahij
Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro Martínez-Gómez,
Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh, Mónica
López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl3-1479164119892137">
      <caption>
        <title>Online_appendix_3_Table – Supplemental material for Prediction of major
adverse cardiac, cerebrovascular events in patients with diabetes after
acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_3_Table.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_3_Table for Prediction of major adverse
cardiac, cerebrovascular events in patients with diabetes after acute coronary
syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto Cordero, Bahij
Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro Martínez-Gómez,
Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh, Mónica
López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl4-1479164119892137">
      <caption>
        <title>Online_appendix_4_calibration_by_year_macce – Supplemental material for
Prediction of major adverse cardiac, cerebrovascular events in patients with
diabetes after acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_4_calibration_by_year_macce.tiff">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_4_calibration_by_year_macce for Prediction
of major adverse cardiac, cerebrovascular events in patients with diabetes after
acute coronary syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto
Cordero, Bahij Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro
Martínez-Gómez, Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh,
Mónica López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl5-1479164119892137">
      <caption>
        <title>Online_appendix_5_flowchart_MACCE – Supplemental material for Prediction
of major adverse cardiac, cerebrovascular events in patients with diabetes
after acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_5_flowchart_MACCE.tiff">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_5_flowchart_MACCE for Prediction of major
adverse cardiac, cerebrovascular events in patients with diabetes after acute
coronary syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto Cordero,
Bahij Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro
Martínez-Gómez, Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh,
Mónica López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl6-1479164119892137">
      <caption>
        <title>Online_appendix_6_Web_App_PGHR_score_final_MACCE – Supplemental material
for Prediction of major adverse cardiac, cerebrovascular events in patients
with diabetes after acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_6_Web_App_PGHR_score_final_MACCE.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_6_Web_App_PGHR_score_final_MACCE for
Prediction of major adverse cardiac, cerebrovascular events in patients with
diabetes after acute coronary syndrome by Aurora Baluja, Moisés
Rodríguez-Mañero, Alberto Cordero, Bahij Kreidieh, Diego Iglesias-Alvarez, Jose
M García-Acuña, Alvaro Martínez-Gómez, Rosa Agra-Bermejo, Leyre
Alvarez-Rodríguez, Charigan Abou-Jokh, Mónica López-Ratón, Francisco
Gude-Sampedro, Julián Alvarez-Escudero and Jose R González-Juanatey in Diabetes
&amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl7-1479164119892137">
      <caption>
        <title>Online_appendix_7_survival_macce_kaplan_meier – Supplemental material for
Prediction of major adverse cardiac, cerebrovascular events in patients with
diabetes after acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_7_survival_macce_kaplan_meier.tiff">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_7_survival_macce_kaplan_meier for
Prediction of major adverse cardiac, cerebrovascular events in patients with
diabetes after acute coronary syndrome by Aurora Baluja, Moisés
Rodríguez-Mañero, Alberto Cordero, Bahij Kreidieh, Diego Iglesias-Alvarez, Jose
M García-Acuña, Alvaro Martínez-Gómez, Rosa Agra-Bermejo, Leyre
Alvarez-Rodríguez, Charigan Abou-Jokh, Mónica López-Ratón, Francisco
Gude-Sampedro, Julián Alvarez-Escudero and Jose R González-Juanatey in Diabetes
&amp; Vascular Disease Research</p>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="suppl8-1479164119892137">
      <caption>
        <title>Online_appendix_8_Table_survival_macce – Supplemental material for
Prediction of major adverse cardiac, cerebrovascular events in patients with
diabetes after acute coronary syndrome</title>
      </caption>
      <media xlink:href="Online_appendix_8_Table_survival_macce.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
      <p>Supplemental material, Online_appendix_8_Table_survival_macce for Prediction of
major adverse cardiac, cerebrovascular events in patients with diabetes after
acute coronary syndrome by Aurora Baluja, Moisés Rodríguez-Mañero, Alberto
Cordero, Bahij Kreidieh, Diego Iglesias-Alvarez, Jose M García-Acuña, Alvaro
Martínez-Gómez, Rosa Agra-Bermejo, Leyre Alvarez-Rodríguez, Charigan Abou-Jokh,
Mónica López-Ratón, Francisco Gude-Sampedro, Julián Alvarez-Escudero and Jose R
González-Juanatey in Diabetes &amp; Vascular Disease Research</p>
    </supplementary-material>
  </sec>
</body>
<back>
  <fn-group>
    <fn fn-type="COI-statement">
      <p><bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship and/or publication of this article.</p>
    </fn>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p>
    </fn>
    <fn fn-type="other">
      <p><bold>ORCID iDs:</bold> Aurora Baluja <inline-graphic xlink:href="10.1177_1479164119892137-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-5204-0771">https://orcid.org/0000-0002-5204-0771</ext-link></p>
      <p>Moisés Rodríguez-Mañero <inline-graphic xlink:href="10.1177_1479164119892137-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-7566-9321">https://orcid.org/0000-0001-7566-9321</ext-link></p>
    </fn>
    <fn fn-type="supplementary-material">
      <p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="bibr1-1479164119892137">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>PR</given-names></name><name><surname>Fuster</surname><given-names>V.</given-names></name></person-group><article-title>New aspects in the pathogenesis of diabetic
atherothrombosis</article-title>. <source>J Am Coll Cardiol</source><year>2004</year>; <volume>44</volume>:
<fpage>2293</fpage>–<lpage>2300</lpage>.<pub-id pub-id-type="pmid">15607389</pub-id></mixed-citation>
    </ref>
    <ref id="bibr2-1479164119892137">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>NA</given-names></name><name><surname>Moorthy</surname><given-names>MV</given-names></name><name><surname>Pester</surname><given-names>JJ</given-names></name></person-group>, <etal>et al</etal><article-title>Sudden death in patients
with coronary heart disease without severe systolic
dysfunction</article-title>. <source>JAMA Cardiol</source><year>2018</year>; <volume>3</volume>:
<fpage>591</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">29801082</pub-id></mixed-citation>
    </ref>
    <ref id="bibr3-1479164119892137">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordero</surname><given-names>AA</given-names></name><name><surname>Lopez-Palop</surname><given-names>R</given-names></name><name><surname>Carrillo</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal><article-title>Comparison of long-term
mortality for cardiac diseases in patients with versus without diabetes
mellitus</article-title>. <source>Am J Cardiol</source><year>2016</year>; <volume>117</volume>:
<fpage>1088</fpage>–<lpage>1094</lpage>.<pub-id pub-id-type="pmid">26851962</pub-id></mixed-citation>
    </ref>
    <ref id="bibr4-1479164119892137">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Yusuf</surname><given-names>SS</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name></person-group>, <etal>et al</etal><article-title>Impact of diabetes on
long-term prognosis in patients with unstable angina and non-Q-wave
myocardial infarction: results of the OASIS (Organization to Assess
Strategies for Ischemic Syndromes) registry</article-title>.
<source>Circulation</source><year>2000</year>; <volume>102</volume>:
<fpage>1014</fpage>–<lpage>1019</lpage>.<pub-id pub-id-type="pmid">10961966</pub-id></mixed-citation>
    </ref>
    <ref id="bibr5-1479164119892137">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Velazquez</surname><given-names>EJ</given-names></name></person-group>, <etal>et al</etal><article-title>Valsartan, captopril, or
both in myocardial infarction complicated by heart failure, left ventricular
dysfunction, or both</article-title>. <source>N Engl J Med</source><year>2003</year>; <volume>349</volume>:
<fpage>1893</fpage>–<lpage>1906</lpage>.<pub-id pub-id-type="pmid">14610160</pub-id></mixed-citation>
    </ref>
    <ref id="bibr6-1479164119892137">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junttila</surname><given-names>MJ</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><name><surname>Myerburg</surname><given-names>RJ</given-names></name></person-group>, <etal>et al</etal><article-title>Sudden cardiac death after
myocardial infarction in patients with type 2 diabetes</article-title>.
<source>Heart Rhythm</source><year>2010</year>; <volume>7</volume>:
<fpage>1396</fpage>–<lpage>1403</lpage>.<pub-id pub-id-type="pmid">20682359</pub-id></mixed-citation>
    </ref>
    <ref id="bibr7-1479164119892137">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baeza-Roman</surname><given-names>AA</given-names></name><name><surname>de Miguel-Balsa</surname><given-names>E</given-names></name><name><surname>Latour-Perez</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Predictive power of the
grace score in population with diabetes</article-title>. <source>Int J
Cardiol</source><year>2017</year>; <volume>248</volume>:
<fpage>73</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">28747270</pub-id></mixed-citation>
    </ref>
    <ref id="bibr8-1479164119892137">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibanez</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>S</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal><article-title>2017 ESC Guidelines for the
management of acute myocardial infarction in patients presenting with
ST-segment elevation: the Task Force for the management of acute myocardial
infarction in patients presenting with ST-segment elevation of the European
Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source><year>2018</year>; <volume>39</volume>:
<fpage>119</fpage>–<lpage>177</lpage>.<pub-id pub-id-type="pmid">28886621</pub-id></mixed-citation>
    </ref>
    <ref id="bibr9-1479164119892137">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>EA</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name></person-group>, <etal>et al</etal><article-title>2014 AHA/ACC guideline for
the management of patients with non-ST-elevation acute coronary syndromes: a
report of the American College of Cardiology/American Heart Association Task
Force on practice guidelines</article-title>. <source>J Am Coll
Cardiol</source><year>2014</year>; <volume>64</volume>: e139–e228.</mixed-citation>
    </ref>
    <ref id="bibr10-1479164119892137">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y-JYJ</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names></name></person-group>, <etal>et al</etal><article-title>Optimal medical therapy
improves clinical outcomes in patients undergoing revascularization with
percutaneous coronary intervention or coronary artery bypass grafting:
insights from the Synergy Between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year
follow-up</article-title>. <source>Circulation</source><year>2015</year>; <volume>131</volume>:
<fpage>1269</fpage>–<lpage>1277</lpage>.<pub-id pub-id-type="pmid">25847979</pub-id></mixed-citation>
    </ref>
    <ref id="bibr11-1479164119892137">
      <label>11</label>
      <mixed-citation publication-type="journal"><collab>National Kidney Foundation</collab>. <article-title>K/DOQI clinical
practice guidelines for chronic kidney disease: evaluation, classification,
and stratification</article-title>. <source>Am J Kidney Dis</source><year>2002</year>; <volume>39</volume>: S1–S266.</mixed-citation>
    </ref>
    <ref id="bibr12-1479164119892137">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>LL</given-names></name><name><surname>Rodrigues</surname><given-names>A</given-names></name><name><surname>Carvalho</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal><article-title>Modelling competing risks in
nephrology research: an example in peritoneal dialysis</article-title>.
<source>BMC Nephrol</source><year>2013</year>; <volume>14</volume>: <fpage>110</fpage>.<pub-id pub-id-type="pmid">23705871</pub-id></mixed-citation>
    </ref>
    <ref id="bibr13-1479164119892137">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ.</given-names></name></person-group><article-title>A proportional hazards model for the subdistribution of a
competing risk</article-title>. <source>J Am Stat Assoc</source><year>1999</year>; <volume>94</volume>:
<fpage>496</fpage>–<lpage>509</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr14-1479164119892137">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Lee</surname><given-names>DS</given-names></name><name><surname>D’Agostino</surname><given-names>RB</given-names></name></person-group>, <etal>et al</etal><article-title>Developing points-based
risk-scoring systems in the presence of competing risks</article-title>.
<source>Stat Med</source><year>2016</year>; <volume>35</volume>:
<fpage>4056</fpage>–<lpage>4072</lpage>.<pub-id pub-id-type="pmid">27197622</pub-id></mixed-citation>
    </ref>
    <ref id="bibr15-1479164119892137">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal><article-title>Lifestyle and impact on
cardiovascular risk factor control in coronary patients across 27 countries:
results from the European Society of Cardiology ESC-EORP EUROASPIRE V
registry</article-title>. <source>Eur J Prev Cardiol</source><year>2019</year>; <volume>26</volume>:
<fpage>824</fpage>–<lpage>835</lpage>.<pub-id pub-id-type="pmid">30739508</pub-id></mixed-citation>
    </ref>
    <ref id="bibr16-1479164119892137">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stecker</surname><given-names>EC</given-names></name><name><surname>Vickers</surname><given-names>CC</given-names></name><name><surname>Waltz</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Population-based analysis of
sudden cardiac death with and without left ventricular systolic dysfunction:
Two-year findings from the Oregon Sudden Unexpected Death
Study</article-title>. <source>J Am Coll Cardiol</source><year>2006</year>; <volume>47</volume>:
<fpage>1161</fpage>–<lpage>1166</lpage>.<pub-id pub-id-type="pmid">16545646</pub-id></mixed-citation>
    </ref>
    <ref id="bibr17-1479164119892137">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaduganathan</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>RB</given-names></name><name><surname>Michel</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Mode of death in heart
failure with preserved ejection fraction</article-title>. <source>J Am Coll
Cardiol</source><year>2017</year>; <volume>69</volume>:
<fpage>556</fpage>–<lpage>569</lpage>.<pub-id pub-id-type="pmid">28153111</pub-id></mixed-citation>
    </ref>
    <ref id="bibr18-1479164119892137">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savonitto</surname><given-names>S</given-names></name><name><surname>Morici</surname><given-names>N</given-names></name><name><surname>Nozza</surname><given-names>A</given-names></name></person-group>, <etal>et al</etal><article-title>Predictors of mortality in
hospital survivors with type 2 diabetes mellitus and acute coronary
syndromes</article-title>. <source>Diab Vasc Dis Res</source><year>2018</year>; <volume>15</volume>:
<fpage>14</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">29052439</pub-id></mixed-citation>
    </ref>
    <ref id="bibr19-1479164119892137">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolsk</surname><given-names>E</given-names></name><name><surname>Claggett</surname><given-names>B</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal><article-title>Role of B-Type natriuretic
peptide and N-terminal prohormone BNP as predictors of cardiovascular
morbidity and mortality in patients with a recent coronary event and Type 2
diabetes mellitus</article-title>. <source>J Am Heart Assoc</source><year>2017</year>; <volume>6</volume>: e004743.</mixed-citation>
    </ref>
    <ref id="bibr20-1479164119892137">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>VV</given-names></name><name><surname>Stegmayr</surname><given-names>B</given-names></name><name><surname>Asplund</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal><article-title>Diabetes as a risk factor
for myocardial infarction: population and gender
perspectives</article-title>. <source>J Intern Med</source><year>1997</year>; <volume>241</volume>:
<fpage>485</fpage>–<lpage>492</lpage>.<pub-id pub-id-type="pmid">10497624</pub-id></mixed-citation>
    </ref>
    <ref id="bibr21-1479164119892137">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordero</surname><given-names>AA</given-names></name><name><surname>Bertomeu-Gonzalez</surname><given-names>V</given-names></name><name><surname>Moreno-Arribas</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal><article-title>Prognosis and lipid profile
improvement by a specialized outpatient clinic for acute coronary syndrome
patients</article-title>. <source>Atherosclerosis</source><year>2018</year>; <volume>275</volume>:
<fpage>28</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">29852402</pub-id></mixed-citation>
    </ref>
    <ref id="bibr22-1479164119892137">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Packer</surname><given-names>M</given-names></name><name><surname>Desai</surname><given-names>AS</given-names></name></person-group>, <etal>et al</etal><article-title>Angiotensin-neprilysin
inhibition versus enalapril in heart failure</article-title>. <source>N Engl
J Med</source><year>2014</year>; <volume>371</volume>:
<fpage>993</fpage>–<lpage>1004</lpage>.<pub-id pub-id-type="pmid">25176015</pub-id></mixed-citation>
    </ref>
    <ref id="bibr23-1479164119892137">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Diego</surname><given-names>CC</given-names></name><name><surname>Gonzalez-Torres</surname><given-names>L</given-names></name><name><surname>Nunez</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal><article-title>Effects of
angiotensin-neprilysin inhibition compared to angiotensin inhibition on
ventricular arrhythmias in reduced ejection fraction patients under
continuous remote monitoring of implantable defibrillator
devices</article-title>. <source>Heart Rhythm</source><year>2018</year>; <volume>15</volume>:
<fpage>395</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">29146274</pub-id></mixed-citation>
    </ref>
    <ref id="bibr24-1479164119892137">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardy</surname><given-names>GH</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Mark</surname><given-names>DB</given-names></name></person-group>, <etal>et al</etal><article-title>Amiodarone or an implantable
cardioverter-defibrillator for congestive heart failure</article-title>.
<source>N Engl J Med</source><year>2009</year>; <volume>352</volume>:
<fpage>225</fpage>–<lpage>237</lpage>.</mixed-citation>
    </ref>
    <ref id="bibr25-1479164119892137">
      <label>25</label>
      <mixed-citation publication-type="gov"><collab>Prospective ARNI vs ACE inhibitor trial to determine superiority in
reducing heart failure events after MI</collab>.
<source>ClinicalTrials.gov</source>, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02924727">https://clinicaltrials.gov/ct2/show/NCT02924727</ext-link>
(<comment>accessed 7 March 2019</comment>).</mixed-citation>
    </ref>
    <ref id="bibr26-1479164119892137">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutyifa</surname><given-names>V</given-names></name><name><surname>Beck</surname><given-names>CC</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name></person-group>, <etal>et al</etal><article-title>Multicenter Automatic
Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter
Defibrillator (MADIT S-ICD): design and clinical protocol</article-title>.
<source>Am Heart J</source><year>2017</year>; <volume>189</volume>:
<fpage>158</fpage>–<lpage>166</lpage>.<pub-id pub-id-type="pmid">28625372</pub-id></mixed-citation>
    </ref>
    <ref id="bibr27-1479164119892137">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFilippis</surname><given-names>AP</given-names></name><name><surname>Young</surname><given-names>RR</given-names></name><name><surname>Carrubba</surname><given-names>CJ</given-names></name></person-group>, <etal>et al</etal><article-title>An analysis of calibration
and discrimination among multiple cardiovascular risk scores in a modern
multiethnic cohort</article-title>. <source>Ann Intern Med</source><year>2015</year>; <volume>162</volume>:
<fpage>266</fpage>–<lpage>275</lpage>.<pub-id pub-id-type="pmid">25686167</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
